Evidence map›Paper›PMID 41217626›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Nonclinical investigations of a novel heart-type fatty acid-binding protein ligand, [

Jun Toyohara, Masahiko Ito, Muneyuki Sakata, Tetsuro Tago, Taichi Komoda, Hiroshi Yoshino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jun ToyoharaResearch Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan. toyohara@pet.tmig.or.jp.ORCID http://orcid.org/0000-0003-4721-405X
Masahiko ItoR&D Center, Shiratori Pharmaceuticals Co., Ltd, Narashino, Japan.
Muneyuki SakataResearch Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan.
Tetsuro TagoResearch Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173-0015, Japan.
Taichi KomodaR&D Center, Shiratori Pharmaceuticals Co., Ltd, Narashino, Japan.
Hiroshi YoshinoR&D Center, Shiratori Pharmaceuticals Co., Ltd, Narashino, Japan.

Funding

Japan Society for the Promotion of Science 21K07663Japan Society for the Promotion of Science 24K10776Shiratori Pharmaceuticals Shiratori Pharmaceuticals
6 · The paper itself

Abstract

backgroundHeart-type fatty acid-binding protein (FABP3) mediates the intracellular transport of fatty acids and is highly expressed in the myocardium. During myocardial infarction, FABP3 leaks from the myocardial cytoplasm into the blood; thus, detection of FABP3 using positron emission tomography (PET) is useful in identifying the site of myocardial damage. 4-(4-Fluoro-2-(1-phenyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)phenoxy)butanoic acid (LUF) is a small-molecule organic compound that specifically binds FABP3. We confirmed that fluorine-18-labeled LUF enables clear, high-quality visualization of the myocardium as well as lesions associated with myocardial injury. In this study, we performed a process validation of [

resultsThe activity yield of [

conclusions[

Indexed as

DosimetryFluorine-18Heart-type fatty acid–binding proteinPositron emission tomographyToxicology

Identifiers

PMID41217626
PMCPMC12605672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.